Decode announced last week that it had granted Celera non-exclusive worldwide rights to genetic markers for various cardiovascular and metabolic diseases.

The deal will give cash-strapped Decode immediate access to an undisclosed sum in upfront payments, while Celera will gain access to gene markers that will complement and expand its cardiovascular disease-focused genetic testing service.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.